Sanofi - ADR
SNY
Market Cap$127.23B
Close$
Earnings Call Q4 2024
January 30, 2025 - AI Summary
Strong Sales Growth: Sanofi reported Q4 net sales of €10.6 billion, marking a 10.3% year-over-year growth at constant exchange rates and achieving double-digit growth for the third consecutive quarter. Full-year net sales increased by 11.3% to €41.1 billion, driven by product launches and strong performances from Dupixent and Beyfortus.
Dupixent Performance: Dupixent exceeded expectations with sales surpassing €13 billion for 2024, reflecting a 23% growth driven by strong prescription trends globally. In Q4 alone, sales grew by 16%, although impacted by one-off adjustments related to gross to net calculations and fewer business days.
Beyfortus Achievements and Competition: Beyfortus recorded almost €1.7 billion in sales during its first full year, benefiting from a significant launch and resulting in more than 6 million babies treated. However, competition is expected to increase with the potential approval of clesrovimab, which could impact future growth.
Exclusive for Stockcircle Pro members
Sign up
$95.18
83.6% upside
Current Fair Value
83.6% upsideUndervalued by 83.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $127.23 Billion |
|---|---|
| Enterprise Value | $138.83 Billion |
| Dividend Yield | $2.03691 (4.14507772020725%) |
| Earnings per Share | $2.22 |
| Beta | 0.48 |
| Outstanding Shares | 1,253,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 20.44 |
|---|---|
| PEG | -27.38 |
| Price to Sales | 1.21 |
| Price to Book Ratio | 0.84 |
| Enterprise Value to Revenue | 2.57 |
| Enterprise Value to EBIT | 12.59 |
| Enterprise Value to Net Income | 20 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Sanofi
CEO: Paul Hudson Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the c...